T. Rowe Price Associates
DAWN

T. Rowe Price Associates’s Day One Biopharmaceuticals DAWN Stock Holding History

T. Rowe Price Associates’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.56M Buy
119,288
+16,832
+16% +$237K ﹤0.01% 1723
2025
Q4 		$955K Buy
102,456
+22,723
+28% +$190K ﹤0.01% 2103
2025
Q3 		$563K Sell
79,733
-1,040,898
-93% -$7.16M ﹤0.01% 2314
2025
Q2 		$7.29M Sell
1,120,631
-52,463
-4% -$361K ﹤0.01% 1190
2025
Q1 		$9.3M Sell
1,173,094
-533,018
-31% -$5.74M ﹤0.01% 1126
2024
Q4 		$21.6M Sell
1,706,112
-838,751
-33% -$11.7M ﹤0.01% 980
2024
Q3 		$35.5M Buy
2,544,863
+193,983
+8% +$2.77M ﹤0.01% 848
2024
Q2 		$32.4M Buy
2,350,880
+51,116
+2% +$748K ﹤0.01% 839
2024
Q1 		$38M Sell
2,299,764
-17,000
-0.7% -$254K ﹤0.01% 792
2023
Q4 		$33.8M Buy
2,316,764
+8,736
+0.4% +$106K ﹤0.01% 808
2023
Q3 		$28.3M Sell
2,308,028
-1,703
-0.1% -$22.2K ﹤0.01% 833
2023
Q2 		$27.6M Buy
2,309,731
+644,980
+39% +$8.42M ﹤0.01% 850
2023
Q1 		$22.3M Sell
1,664,751
-517,827
-24% -$10.1M ﹤0.01% 895
2022
Q4 		$47M Buy
2,182,578
+87,665
+4% +$1.8M 0.01% 677
2022
Q3 		$42M Buy
2,094,913
+53,569
+3% +$1.14M 0.01% 699
2022
Q2 		$36.5M Buy
2,041,344
+455,603
+29% +$4.7M ﹤0.01% 984
2022
Q1 		$15.7M Buy
1,585,741
+4,763
+0.3% +$62.9K ﹤0.01% 1293
2021
Q4 		$26.6M Buy
1,580,978
+74,652
+5% +$1.53M ﹤0.01% 1208
2021
Q3 		$34.9M Buy
1,506,326
+930
+0.1% +$22.3K ﹤0.01% 1136
2021
Q2 		$33.4M Buy
+1,505,396
New +$31.4M ﹤0.01% 1168

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

T. Rowe Price Associates's DAWN Position: Q1 2026 in Review

T. Rowe Price Associates increased its Day One Biopharmaceuticals (DAWN) stake by 16% in Q1 2026, buying an estimated $237K and bringing the position to 119,288 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1723.

T. Rowe Price Associates first reported a position in DAWN in Q2 2021 and has held it in 20 quarters since. The position peaked at $47M in Q4 2022. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • T. Rowe Price Associates held 119,288 shares of Day One Biopharmaceuticals worth $2.56M as of Q1 2026.
  • T. Rowe Price Associates bought 16,832 Day One Biopharmaceuticals shares in Q1 2026, an estimated $237K.
  • Day One Biopharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1723 holding.
  • T. Rowe Price Associates first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • T. Rowe Price Associates's Day One Biopharmaceuticals position peaked at $47M in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.